View Future GrowthCGN Nuclear Technology Development 過去の業績過去 基準チェック /06CGN Nuclear Technology Developmentの収益は年間平均-53.3%の割合で減少していますが、 Chemicals業界の収益は年間 減少しています。収益は年間5.6% 7.6%割合で 減少しています。主要情報-53.34%収益成長率-53.34%EPS成長率Chemicals 業界の成長12.10%収益成長率-7.58%株主資本利益率-5.47%ネット・マージン-5.04%前回の決算情報31 Mar 2026最近の業績更新お知らせ • Mar 31CGN Nuclear Technology Development Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026CGN Nuclear Technology Development Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026お知らせ • Dec 31CGN Nuclear Technology Development Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026CGN Nuclear Technology Development Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026お知らせ • Sep 30CGN Nuclear Technology Development Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025CGN Nuclear Technology Development Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025お知らせ • Jul 02CGN Nuclear Technology Development Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025CGN Nuclear Technology Development Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025お知らせ • Mar 31CGN Nuclear Technology Development Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025CGN Nuclear Technology Development Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025お知らせ • Dec 31CGN Nuclear Technology Development Co., Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025CGN Nuclear Technology Development Co., Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025すべての更新を表示Recent updatesBoard Change • May 20High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Xiaoyan Huang is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 28CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, May 18, 2026CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, May 18, 2026, at 15:00 China Standard Time. Location: The Company's Meeting Room, Shenzhen, Guangdong Chinaお知らせ • Mar 31CGN Nuclear Technology Development Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026CGN Nuclear Technology Development Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026お知らせ • Dec 31CGN Nuclear Technology Development Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026CGN Nuclear Technology Development Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026お知らせ • Sep 30CGN Nuclear Technology Development Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025CGN Nuclear Technology Development Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025お知らせ • Jul 02CGN Nuclear Technology Development Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025CGN Nuclear Technology Development Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025お知らせ • Jun 09CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, Jun 30, 2025CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, Jun 30, 2025, at 14:30 China Standard Time. Location: 19F, North Tower, No. 2002, Shennan Avenue, Futian District, Shenzhen, Guangdong Chinaお知らせ • Apr 01CGN Nuclear Technology Development Co., Ltd. Approves the Election of Yu Haifeng as Non-Independent DirectorCGN Nuclear Technology Development Co., Ltd. held its 2nd Extraordinary General Meeting of 2025 on 28 March 2025, during which the following proposal(s) was/were approved: Election of Yu Haifeng as a non-independent director.お知らせ • Mar 31CGN Nuclear Technology Development Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025CGN Nuclear Technology Development Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025お知らせ • Feb 18CGN Nuclear Technology Development Co., Ltd. Approves Board ElectionsCGN Nuclear Technology Development Co., Ltd. at its Extraordinary General Meeting held on 14 February 2025, approved the election of Wang Man and He Fei as non-independent director.お知らせ • Dec 31CGN Nuclear Technology Development Co., Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025CGN Nuclear Technology Development Co., Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025Reported Earnings • Oct 31Third quarter 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.001 profit in 3Q 2023)Third quarter 2024 results: CN¥0.05 loss per share (down from CN¥0.001 profit in 3Q 2023). Revenue: CN¥1.67b (flat on 3Q 2023). Net loss: CN¥47.8m (down CN¥48.7m from profit in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 108 percentage points per year, which is a significant difference in performance.お知らせ • Sep 30CGN Nuclear Technology Development Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024CGN Nuclear Technology Development Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024お知らせ • Aug 30CGN Nuclear Technology Development Co., Ltd. Approves Election of Mou Wenjun as A Non-Independent DirectorCGN Nuclear Technology Development Co., Ltd. held its Extraordinary General Meeting of 2024 on 28 August 2024 approved Election of Mou Wenjun as a non-independent director.お知らせ • Jun 29CGN Nuclear Technology Development Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024CGN Nuclear Technology Development Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024お知らせ • Apr 29CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, May 17, 2024CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, May 17, 2024, at 14:30 China Standard Time. Location: 19F, North Tower, No. 2002, Shennan Avenue, Futian District, Shenzhen, Guangdong Chinaお知らせ • Mar 30CGN Nuclear Technology Development Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024CGN Nuclear Technology Development Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024お知らせ • Jan 16CGN Nuclear Technology Development Co., Ltd. Approves Board ElectionsCGN Nuclear Technology Development Co., Ltd. announced that at its EGM held on 12 January 2024, the shareholders approved election of Mu Changkun and Wu Yuanming as non-independent directors of the company.お知らせ • Dec 30CGN Nuclear Technology Development Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024CGN Nuclear Technology Development Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024New Risk • Dec 21New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 242% Earnings have declined by 23% per year over the past 5 years.Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.092 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.001 (down from CN¥0.092 in 3Q 2022). Revenue: CN¥1.68b (down 23% from 3Q 2022). Net income: CN¥939.9k (down 99% from 3Q 2022). Profit margin: 0.1% (down from 4.0% in 3Q 2022). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 26Second quarter 2023 earnings released: CN¥0.084 loss per share (vs CN¥0.091 profit in 2Q 2022)Second quarter 2023 results: CN¥0.084 loss per share (down from CN¥0.091 profit in 2Q 2022). Revenue: CN¥1.64b (down 30% from 2Q 2022). Net loss: CN¥78.9m (down 192% from profit in 2Q 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.お知らせ • Jun 02CGN Nuclear Technology Development Co., Ltd. Announces Cash Dividend of A Shares for the Year 2022, Payment Date Is 07 June 2023CGN Nuclear Technology Development Co., Ltd. announced cash dividend/10 shares (tax included) of CNY 0.4000000 of A shares for the year 2022. Record date is 06 June 2023. Ex-date is 07 June 2023. Payment date 07 June 2023.Reported Earnings • Apr 28First quarter 2023 earnings released: CN¥0.027 loss per share (vs CN¥0.04 profit in 1Q 2022)First quarter 2023 results: CN¥0.027 loss per share (down from CN¥0.04 profit in 1Q 2022). Revenue: CN¥1.23b (down 38% from 1Q 2022). Net loss: CN¥25.7m (down 168% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Board Change • Feb 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Employee Supervisor Jun Wang was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 21CGN Nuclear Technology Development Co., Ltd. Approves Management ElectionsCGN Nuclear Technology Development Co., Ltd. at its Extraordinary General Meeting held on 19 January 2023 approved election of Sheng Guofu and Wen Zhitao as non-independent director, Huang Xiaoyan and Kang Xiaoyue as independent director and Yang Jun and Wang Jun as non-employee supervisor.Board Change • Nov 16Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Chengqing Liu is the most experienced director on the board, commencing their role in 2020. Independent Director Guangguo Sun was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Oct 31Third quarter 2022 earnings released: EPS: CN¥0.092 (vs CN¥0.079 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.092 (up from CN¥0.079 in 3Q 2021). Revenue: CN¥2.17b (up 1.2% from 3Q 2021). Net income: CN¥87.5m (up 17% from 3Q 2021). Profit margin: 4.0% (up from 3.5% in 3Q 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 28Second quarter 2022 earnings released: EPS: CN¥0.091 (vs CN¥0.11 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.091 (down from CN¥0.11 in 2Q 2021). Revenue: CN¥2.35b (up 24% from 2Q 2021). Net income: CN¥85.7m (down 19% from 2Q 2021). Profit margin: 3.6% (down from 5.6% in 2Q 2021). Over the next year, revenue is forecast to grow 3.1%, compared to a 39% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 5% per year.Reported Earnings • May 02First quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.025 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.04 (up from CN¥0.025 in 1Q 2021). Revenue: CN¥1.96b (up 37% from 1Q 2021). Net income: CN¥38.1m (up 63% from 1Q 2021). Profit margin: 1.9% (up from 1.6% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 1.1%, compared to a 42% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat.Valuation Update With 7 Day Price Move • Apr 28Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to CN¥7.95, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 14x in the Chemicals industry in China. Total loss to shareholders of 11% over the past three years.Board Change • Apr 27Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Chengqing Liu is the most experienced director on the board, commencing their role in 2020. Independent Director Guangguo Sun was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Valuation Update With 7 Day Price Move • Mar 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥10.24, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 18x in the Chemicals industry in China. Total returns to shareholders of 14% over the past three years.Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.079 (vs CN¥0.058 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥2.14b (up 21% from 3Q 2020). Net income: CN¥74.7m (up 37% from 3Q 2020). Profit margin: 3.5% (up from 3.1% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.28 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥1.90b (down 6.3% from 2Q 2020). Net income: CN¥106.0m (down 59% from 2Q 2020). Profit margin: 5.6% (down from 13% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.Reported Earnings • May 02First quarter 2021 earnings released: EPS CN¥0.025 (vs CN¥0.066 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥1.43b (up 53% from 1Q 2020). Net income: CN¥23.4m (up CN¥85.6m from 1Q 2020). Profit margin: 1.6% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.Reported Earnings • Apr 17Full year 2020 earnings released: EPS CN¥0.29 (vs CN¥0.10 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: CN¥6.65b (down 5.3% from FY 2019). Net income: CN¥271.1m (up 164% from FY 2019). Profit margin: 4.1% (up from 1.5% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Mar 16New 90-day high: CN¥12.08The company is up 41% from a price of CN¥8.56 on 16 December 2020. Outperformed the Chinese market which is down 2.0% over the last 90 days. Exceeded the Chemicals industry, which is up 10.0% over the same period.Valuation Update With 7 Day Price Move • Feb 09Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to CN¥9.32, the stock is trading at a trailing P/E ratio of 31.5x, down from the previous P/E ratio of 37.3x. This compares to an average P/E of 34x in the Chemicals industry in China. Total return to shareholders over the past three years is a loss of 14%.Is New 90 Day High Low • Jan 15New 90-day high: CN¥11.22The company is up 14% from its price of CN¥9.80 on 16 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥49.63 per share.Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 21% share price gain to CN¥10.73, the stock is trading at a trailing P/E ratio of 36.9x, up from the previous P/E ratio of 30.4x. This compares to an average P/E of 35x in the Chemicals industry in China. Total return to shareholders over the past three years is a loss of 18%.Is New 90 Day High Low • Dec 29New 90-day high: CN¥10.73The company is up 13% from its price of CN¥9.50 on 30 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period.Is New 90 Day High Low • Oct 30New 90-day low: CN¥8.81The company is down 5.0% from its price of CN¥9.23 on 31 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period.Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥280.7m, up 37% from the prior year. Total revenue was CN¥7.10b over the last 12 months, up 6.7% from the prior year.収支内訳CGN Nuclear Technology Development の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史XSEC:000881 収益、費用、利益 ( )CNY Millions日付収益収益G+A経費研究開発費31 Mar 265,573-28183220031 Dec 255,553-28783719830 Sep 255,776-33086619130 Jun 255,934-37591619031 Mar 255,920-36291019631 Dec 246,168-36291020530 Sep 246,265-76892922430 Jun 246,385-71988123931 Mar 246,436-77788824031 Dec 236,353-73788723530 Sep 235,006-11572622530 Jun 235,425-2977521531 Mar 236,20713675322131 Dec 226,94520079023130 Sep 229,00518485425130 Jun 228,98017184924131 Mar 228,53219187623431 Dec 217,99917787823830 Sep 217,38922288223130 Jun 217,02020183424031 Mar 217,14835778723901 Jan 216,65227171522330 Sep 207,10128169722130 Jun 207,09425473222331 Mar 206,7632374421331 Dec 197,02210373221330 Sep 196,65020774422230 Jun 196,79525273520531 Mar 196,64531169519931 Dec 186,77632071319330 Sep 186,76434867217830 Jun 186,50336358919831 Mar 186,54638161915731 Dec 176,36339360512630 Sep 175,3413224946030 Jun 174,504329443031 Mar 173,619301334031 Dec 163,015311260030 Sep 162,6591,287215030 Jun 162,3871,191185031 Mar 162,202279224031 Dec 152,137245219030 Sep 152,312-814273030 Jun 152,103-7943000質の高い収益: 000881は現在利益が出ていません。利益率の向上: 000881は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 000881は利益が出ておらず、過去 5 年間で損失は年間53.3%の割合で増加しています。成長の加速: 000881の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 000881は利益が出ていないため、過去 1 年間の収益成長をChemicals業界 ( 3.7% ) と比較することは困難です。株主資本利益率高いROE: 000881は現在利益が出ていないため、自己資本利益率 ( -5.47% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 20:41終値2026/05/25 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CGN Nuclear Technology Development Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Yanli QiBohai Securities Co., Ltd.
お知らせ • Mar 31CGN Nuclear Technology Development Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026CGN Nuclear Technology Development Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026
お知らせ • Dec 31CGN Nuclear Technology Development Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026CGN Nuclear Technology Development Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026
お知らせ • Sep 30CGN Nuclear Technology Development Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025CGN Nuclear Technology Development Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025
お知らせ • Jul 02CGN Nuclear Technology Development Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025CGN Nuclear Technology Development Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025
お知らせ • Mar 31CGN Nuclear Technology Development Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025CGN Nuclear Technology Development Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
お知らせ • Dec 31CGN Nuclear Technology Development Co., Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025CGN Nuclear Technology Development Co., Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025
Board Change • May 20High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Xiaoyan Huang is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 28CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, May 18, 2026CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, May 18, 2026, at 15:00 China Standard Time. Location: The Company's Meeting Room, Shenzhen, Guangdong China
お知らせ • Mar 31CGN Nuclear Technology Development Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026CGN Nuclear Technology Development Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026
お知らせ • Dec 31CGN Nuclear Technology Development Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026CGN Nuclear Technology Development Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026
お知らせ • Sep 30CGN Nuclear Technology Development Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025CGN Nuclear Technology Development Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025
お知らせ • Jul 02CGN Nuclear Technology Development Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025CGN Nuclear Technology Development Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025
お知らせ • Jun 09CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, Jun 30, 2025CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, Jun 30, 2025, at 14:30 China Standard Time. Location: 19F, North Tower, No. 2002, Shennan Avenue, Futian District, Shenzhen, Guangdong China
お知らせ • Apr 01CGN Nuclear Technology Development Co., Ltd. Approves the Election of Yu Haifeng as Non-Independent DirectorCGN Nuclear Technology Development Co., Ltd. held its 2nd Extraordinary General Meeting of 2025 on 28 March 2025, during which the following proposal(s) was/were approved: Election of Yu Haifeng as a non-independent director.
お知らせ • Mar 31CGN Nuclear Technology Development Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025CGN Nuclear Technology Development Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
お知らせ • Feb 18CGN Nuclear Technology Development Co., Ltd. Approves Board ElectionsCGN Nuclear Technology Development Co., Ltd. at its Extraordinary General Meeting held on 14 February 2025, approved the election of Wang Man and He Fei as non-independent director.
お知らせ • Dec 31CGN Nuclear Technology Development Co., Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025CGN Nuclear Technology Development Co., Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025
Reported Earnings • Oct 31Third quarter 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.001 profit in 3Q 2023)Third quarter 2024 results: CN¥0.05 loss per share (down from CN¥0.001 profit in 3Q 2023). Revenue: CN¥1.67b (flat on 3Q 2023). Net loss: CN¥47.8m (down CN¥48.7m from profit in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 108 percentage points per year, which is a significant difference in performance.
お知らせ • Sep 30CGN Nuclear Technology Development Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024CGN Nuclear Technology Development Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024
お知らせ • Aug 30CGN Nuclear Technology Development Co., Ltd. Approves Election of Mou Wenjun as A Non-Independent DirectorCGN Nuclear Technology Development Co., Ltd. held its Extraordinary General Meeting of 2024 on 28 August 2024 approved Election of Mou Wenjun as a non-independent director.
お知らせ • Jun 29CGN Nuclear Technology Development Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024CGN Nuclear Technology Development Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024
お知らせ • Apr 29CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, May 17, 2024CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, May 17, 2024, at 14:30 China Standard Time. Location: 19F, North Tower, No. 2002, Shennan Avenue, Futian District, Shenzhen, Guangdong China
お知らせ • Mar 30CGN Nuclear Technology Development Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024CGN Nuclear Technology Development Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024
お知らせ • Jan 16CGN Nuclear Technology Development Co., Ltd. Approves Board ElectionsCGN Nuclear Technology Development Co., Ltd. announced that at its EGM held on 12 January 2024, the shareholders approved election of Mu Changkun and Wu Yuanming as non-independent directors of the company.
お知らせ • Dec 30CGN Nuclear Technology Development Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024CGN Nuclear Technology Development Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024
New Risk • Dec 21New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 242% Earnings have declined by 23% per year over the past 5 years.
Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.092 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.001 (down from CN¥0.092 in 3Q 2022). Revenue: CN¥1.68b (down 23% from 3Q 2022). Net income: CN¥939.9k (down 99% from 3Q 2022). Profit margin: 0.1% (down from 4.0% in 3Q 2022). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 26Second quarter 2023 earnings released: CN¥0.084 loss per share (vs CN¥0.091 profit in 2Q 2022)Second quarter 2023 results: CN¥0.084 loss per share (down from CN¥0.091 profit in 2Q 2022). Revenue: CN¥1.64b (down 30% from 2Q 2022). Net loss: CN¥78.9m (down 192% from profit in 2Q 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
お知らせ • Jun 02CGN Nuclear Technology Development Co., Ltd. Announces Cash Dividend of A Shares for the Year 2022, Payment Date Is 07 June 2023CGN Nuclear Technology Development Co., Ltd. announced cash dividend/10 shares (tax included) of CNY 0.4000000 of A shares for the year 2022. Record date is 06 June 2023. Ex-date is 07 June 2023. Payment date 07 June 2023.
Reported Earnings • Apr 28First quarter 2023 earnings released: CN¥0.027 loss per share (vs CN¥0.04 profit in 1Q 2022)First quarter 2023 results: CN¥0.027 loss per share (down from CN¥0.04 profit in 1Q 2022). Revenue: CN¥1.23b (down 38% from 1Q 2022). Net loss: CN¥25.7m (down 168% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Board Change • Feb 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Employee Supervisor Jun Wang was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 21CGN Nuclear Technology Development Co., Ltd. Approves Management ElectionsCGN Nuclear Technology Development Co., Ltd. at its Extraordinary General Meeting held on 19 January 2023 approved election of Sheng Guofu and Wen Zhitao as non-independent director, Huang Xiaoyan and Kang Xiaoyue as independent director and Yang Jun and Wang Jun as non-employee supervisor.
Board Change • Nov 16Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Chengqing Liu is the most experienced director on the board, commencing their role in 2020. Independent Director Guangguo Sun was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Oct 31Third quarter 2022 earnings released: EPS: CN¥0.092 (vs CN¥0.079 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.092 (up from CN¥0.079 in 3Q 2021). Revenue: CN¥2.17b (up 1.2% from 3Q 2021). Net income: CN¥87.5m (up 17% from 3Q 2021). Profit margin: 4.0% (up from 3.5% in 3Q 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 28Second quarter 2022 earnings released: EPS: CN¥0.091 (vs CN¥0.11 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.091 (down from CN¥0.11 in 2Q 2021). Revenue: CN¥2.35b (up 24% from 2Q 2021). Net income: CN¥85.7m (down 19% from 2Q 2021). Profit margin: 3.6% (down from 5.6% in 2Q 2021). Over the next year, revenue is forecast to grow 3.1%, compared to a 39% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 5% per year.
Reported Earnings • May 02First quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.025 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.04 (up from CN¥0.025 in 1Q 2021). Revenue: CN¥1.96b (up 37% from 1Q 2021). Net income: CN¥38.1m (up 63% from 1Q 2021). Profit margin: 1.9% (up from 1.6% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 1.1%, compared to a 42% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat.
Valuation Update With 7 Day Price Move • Apr 28Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to CN¥7.95, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 14x in the Chemicals industry in China. Total loss to shareholders of 11% over the past three years.
Board Change • Apr 27Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Chengqing Liu is the most experienced director on the board, commencing their role in 2020. Independent Director Guangguo Sun was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Valuation Update With 7 Day Price Move • Mar 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥10.24, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 18x in the Chemicals industry in China. Total returns to shareholders of 14% over the past three years.
Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.079 (vs CN¥0.058 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥2.14b (up 21% from 3Q 2020). Net income: CN¥74.7m (up 37% from 3Q 2020). Profit margin: 3.5% (up from 3.1% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.28 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥1.90b (down 6.3% from 2Q 2020). Net income: CN¥106.0m (down 59% from 2Q 2020). Profit margin: 5.6% (down from 13% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
Reported Earnings • May 02First quarter 2021 earnings released: EPS CN¥0.025 (vs CN¥0.066 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥1.43b (up 53% from 1Q 2020). Net income: CN¥23.4m (up CN¥85.6m from 1Q 2020). Profit margin: 1.6% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
Reported Earnings • Apr 17Full year 2020 earnings released: EPS CN¥0.29 (vs CN¥0.10 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: CN¥6.65b (down 5.3% from FY 2019). Net income: CN¥271.1m (up 164% from FY 2019). Profit margin: 4.1% (up from 1.5% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Mar 16New 90-day high: CN¥12.08The company is up 41% from a price of CN¥8.56 on 16 December 2020. Outperformed the Chinese market which is down 2.0% over the last 90 days. Exceeded the Chemicals industry, which is up 10.0% over the same period.
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to CN¥9.32, the stock is trading at a trailing P/E ratio of 31.5x, down from the previous P/E ratio of 37.3x. This compares to an average P/E of 34x in the Chemicals industry in China. Total return to shareholders over the past three years is a loss of 14%.
Is New 90 Day High Low • Jan 15New 90-day high: CN¥11.22The company is up 14% from its price of CN¥9.80 on 16 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥49.63 per share.
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 21% share price gain to CN¥10.73, the stock is trading at a trailing P/E ratio of 36.9x, up from the previous P/E ratio of 30.4x. This compares to an average P/E of 35x in the Chemicals industry in China. Total return to shareholders over the past three years is a loss of 18%.
Is New 90 Day High Low • Dec 29New 90-day high: CN¥10.73The company is up 13% from its price of CN¥9.50 on 30 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period.
Is New 90 Day High Low • Oct 30New 90-day low: CN¥8.81The company is down 5.0% from its price of CN¥9.23 on 31 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period.
Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥280.7m, up 37% from the prior year. Total revenue was CN¥7.10b over the last 12 months, up 6.7% from the prior year.